Renée Aguiar-Lucander (Pharmalink AB)

Aguiar-Lucander, Renée (Pharmalink AB 201708 CEO)

	Organisation	Pharmalink AB
	Today	Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
	Group	Calliditas Therapeutics (Group)
	Product	Nefecon®
	Product 2	drug development

Pharmalink AB. (8/15/17). "Press Release: Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications". Stockholm.

The Swedish specialty pharmaceutical company Pharmalink AB today announced the appointment of Fredrik Johansson as new Chief Financial Officer and Mikael Widell as new Head of Communications.

As part of Pharmalink’s preparations for the start of its clinical Phase 3 study with the candidate drug Nefecon, for patients with primary IgA nephropathy, the company has strengthened its management team and appointed Fredrik Johansson as its new CFO.

Prior to joining Pharmalink, Fredrik Johansson was CFO and COO at Birdstep Technology/Techstep ASA, listed on the Oslo Stock Exchange, where he was in charge of the acquisition and reversed listing of Teki Solutions. Previous CFO positions include Phone Family, Teligent Telecom and Wayfinder Systems.

Fredrik Johansson assumed his position on August 1, 2017. Pharmalink's current CFO, Anders Hultman, will remain with the company as Finance Director.

Furthermore, Pharmalink has appointed Mikael Widell to the new position as Head of Communications. Originally a journalist with Sydsvenska Dagbladet and Dagens Industri, Mikael Widell has since 1998 held corporate communications positions at a number of life science companies, including AstraZeneca, Biovitrum and Oasmia. He was also Head of Communications & IR at Sapa and Head of Communications at the private equity firm Nordic Capital. Mikael Widell is a partner and co-founder of the IR/PR firm Cord Communications. He assumed his position with Pharmalink on August 1, 2017.

Renee Aguiar-Lucander, CEO of Pharmalink, said: "Pharmalink is currently in a truly exciting stage of development and we need to ensure that we are fully prepared for the start of the first Phase 3 clinical trial ever conducted in this indication. We are committed to bring Nefecon to patients with IgA nephropathy who risk end-stage renal disease, and I am delighted to welcome Fredrik and Mikael who both bring valuable experience to the company."